Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 2/20 | 0.50 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325383 | 0.86 | ALDH1A1 (0.64) | MAOAMAOBALDH1A1CYP3A4HPGD | |
| SCHEMBL4634307 | 0.85 | CA12 (0.59) | P2RX1TMPRSS4ALDH1A1EPHX2HTT | |
| SCHEMBL5158858 | 0.84 | P2RX1 (0.48) | P2RX1TMPRSS4ALDH1A1EPHX2AKR1C2 | |
| SCHEMBL1505143 | 0.84 | AKR1C2 (0.52) | P2RX1ALDH1A1CYP3A4HPGDAKR1C2 | |
| SCHEMBL5158868 | 0.84 | AKR1C2 (0.52) | P2RX1ALDH1A1CYP3A4HPGDAKR1C2 | |
| SCHEMBL29858917 | 0.83 | P2RX1 (0.51) | P2RX1TMPRSS4ALDH1A1EPHX2WDR5 | |
| SCHEMBL29786514 | 0.83 | ABL1 (0.46) | P2RX1MAOAMAOBEPHX2TGM2 | |
| SCHEMBL9372777 | 0.83 | P2RX1 (0.47) | P2RX1TMPRSS4ALDH1A1HPGDEPHX2 | |
| SCHEMBL17480164 | 0.83 | ABL1 (0.46) | P2RX1MAOAMAOBEPHX2TGM2 | |
| SCHEMBL28783326 | 0.82 | HMGCR (0.45) | P2RX1TMPRSS4ALDH1A1HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20220157484-A1 | POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-2209790-B1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| EP-2209790-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2010-07-28 | — | — | EP | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| EP-2097420-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009062990-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008065508-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-0514942-B1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1997-03-05 | — | — | EP | disclosed |
| US-5493029-A | USEFUL IN TREATING ASTHMA AND HYPERTENSION | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-02-20 | — | — | US | disclosed |
| EP-0514935-B1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1995-11-08 | — | — | EP | disclosed |
| US-5300511-A | Spiro-benzopyran derivatives and useful for treating asthma and hypertension | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1994-04-05 | — | — | US | disclosed |
| US-5236935-A | Hypotensive agents | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-08-17 | — | — | US | disclosed |
| EP-0514935-A1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1992-11-25 | — | — | EP | disclosed |
| EP-0514942-A1 | Novel benzopyran derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1992-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | P2RX1 3408/4885TMPRSS4 2693/4885MAOA 4359/4885 |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | P2RX1 3858/4885TMPRSS4 2636/4885MAOA 3816/4885 |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | P2RX1 170/4885TMPRSS4 1659/4885MAOA 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.